Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.71 |
| ▸ | CA2 | P00918 | 13/20 | 0.71 |
| ▸ | CA9 | Q16790 | 4/20 | 0.71 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | IDE | P14735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6514091 | 0.98 | CA1 (0.69) | CA1CA2CA9ALDH3A1PTGS2 | |
| SCHEMBL14875298 | 0.83 | CA1 (0.49) | CA1CA2CA9ALDH3A1PTGS2 | |
| SCHEMBL1244816 | 0.83 | CA1 (1.00) | CA1CA2CA9SOS1 | |
| Hydrochloric Acid SCHEMBL4735859 | 0.81 | CA1 (0.96) | CA1CA2CA9SOS1 | |
| SCHEMBL6807006 | 0.79 | CA1 (0.44) | CA1CA2CA9ALDH3A1G6PD | |
| SCHEMBL9135441 | 0.79 | SMN1; SMN2 (0.50) | CA1CA2CA9ALDH3A1G6PD | |
| SCHEMBL29173576 | 0.79 | CA1 (0.45) | CA1CA2CA9ALDH3A1PTGS2 | |
| Hydrochloric Acid SCHEMBL6511653 | 0.78 | CA1 (0.43) | CA1CA2CA9ALDH3A1G6PD | |
| SCHEMBL9703261 | 0.78 | CA2 (0.71) | CA1CA2CA9 | |
| SCHEMBL9658757 | 0.77 | KIF11 (0.46) | CA1CA2CA9PTGS2G6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596537-A1 | NOVEL FLUORENE DERIVATIVE COMPOUND AND USE THEREOF | JD Bioscience Inc. (KR) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024071629-A1 | NOVEL FLUORENE DERIVATIVE COMPOUND AND USE THEREOF | (주)제이디바이오사이언스 | 2024-04-04 | — | — | WO | disclosed |
| US-8822480-B2 | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822480-B2 | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2318404-B1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2318404-B1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8410119-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| CN-102417508-A | Fused aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto | ARENA PHARM INC | 2012-04-18 | — | — | CN | disclosed |
| CN-102159572-A | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators | SCHERING CORP | 2011-08-17 | — | — | CN | disclosed |
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2007054668-A1 | SYNTHESIS OF METHYLSULPHONYL BENZENE COMPOUNDS | PEAKDALE MOLECULAR LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICLAS, INC. (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-7132426-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| CN-1829718-A | Fused aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto | ARENA PHARM INC (US) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006076455-A2 | PROCESSES FOR PREPARING PYRAZOLO[3,4-D]PYRIMIDINE ETHERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154940-A1 | Processes for preparing pyrazolo[3,4-d]pyrimidine ethers | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-6727238-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER INC. | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR88, GCGR | CA1 4851/4885CA2 3976/4885CA9 3388/4885 |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | CA1 4863/4885CA2 4651/4885CA9 4137/4885 |
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | CA1 4863/4885CA2 4651/4885CA9 4137/4885 |
| US-20060154940-A1 | Processes for preparing pyrazolo[3,4-d]pyrimidine ethers | DPYD, GCK, PC | CA1 4838/4885CA2 4616/4885CA9 4331/4885 |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | CA1 4863/4885CA2 4651/4885CA9 4137/4885 |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | CA1 4863/4885CA2 4651/4885CA9 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.